    
The links after "Participants" show which Southwest Oncology Group institutions are eligible to participate in this study.
The orange "Where is This Study Open?" tab at the bottom of the page shows the institutions whose Institutional Review Boards (IRBs) have approved the protocol so that it can be opened at that institution. Clicking on the Institution Name will show the points of contact for information about this study at that institution.
|
|
CTSU/E1505
- Phase III Intergroup
|
| A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) |
|
Treatment: Vinorelbine tartrate, Bevacizumab, Cisplatin, Docetaxel, Gemcitabine hydrochloride
Disease Committee: Lung Cancer
|
|
Study Coordinator(s): David R. Gandara, M.D., Eric Vallieres, M.D. Participants: CTSU Eligibility Criteria: The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for more information and registration procedures.
|
Activation Date: 7/1/2007
|
| IRB approval information is not available for CTSU protocols |
